Suppliers and packagers for generic pharmaceutical drug: imetelstat sodium

imetelstat sodium

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779	NDA	Geron Corporation	82959-111-01	1 VIAL, SINGLE-DOSE in 1 CARTON (82959-111-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	2024-06-06
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779	NDA	Geron Corporation	82959-112-01	1 VIAL, SINGLE-DOSE in 1 CARTON (82959-112-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	2024-06-06

Suppliers for the Pharmaceutical Drug: IMETELSTAT SODIUM

Last updated: July 29, 2025

Introduction

Imetelstat sodium, a potent telomerase inhibitor, is a promising therapeutic candidate primarily under development for hematological malignancies, including myelofibrosis and various types of myelodysplastic syndromes (MDS). As a targeted anti-cancer agent, its complex manufacturing process and proprietary nature necessitate a well-established supply chain comprising specialized chemical producers, contract manufacturing organizations (CMOs), and pharmaceutical partners. This article examines the current landscape of suppliers for imetelstat sodium, addressing key vendors, manufacturing developments, and strategic considerations influencing supply chain stability and procurement.

---

Overview of Imetelstat Sodium

Imetelstat sodium (also known by its chemical identifier: GRN163L) is a lipid-conjugated 13-mer oligonucleotide designed to inhibit telomerase activity, resulting in the apoptosis of malignant cells. The compound's synthesis involves advanced oligonucleotide manufacturing techniques, including solid-phase synthesis with specialized modifications. Its complex manufacturing process and stringent quality control requirements mean that only a select group of specialized chemical and biopharmaceutical suppliers can produce pharmaceutical-grade imetelstat sodium.

---

Key Suppliers and Manufacturers

1. Geron Corporation

Geron Corporation, headquartered in Menlo Park, California, is the pioneer and current developer of imetelstat sodium. The company's internal R&D and manufacturing facilities are responsible for the early-stage synthesis and formulation of the compound. While Geron initially managed its supply chain, the company has also partnered with external manufacturers to scale production and meet clinical trial demands.

2. Contract Manufacturing Organizations (CMOs)

Given the specialized nature of oligonucleotide synthesis, several CMOs with expertise in nucleotide production serve as critical suppliers for imetelstat sodium. Notable among these are:

• Lonza Group
  A leading CMOs in custom oligonucleotide synthesis, Lonza offers scalable manufacturing of GMP-grade nucleic acids. It has extensive experience in producing oligonucleotides for clinical and commercial applications, making it a potential supplier of imetelstat sodium or its precursor components.

• Agilent Technologies
  Known for advanced oligonucleotide synthesis platforms, Agilent provides custom synthesis services that include modifications necessary for therapeutic oligonucleotides. Their proprietary technologies enable high-fidelity production vital for drug efficacy and safety.

• Samsung Biologics and SK bioscience
  While primarily focusing on biologics, these companies have expanded their capacities into nucleic acid therapeutics, including custom oligonucleotide manufacturing. Their scalable facilities could potentially produce pharmaceutical-grade imetelstat sodium under contractual agreements.

3. Specialty Chemical Suppliers

The synthesis of imetelstat sodium relies on high-purity chemical reagents, linkers, and phosphoramidites. Suppliers of these include:

• Sigma-Aldrich (MilliporeSigma)
  Supplies specialized reagents for oligonucleotide synthesis, including modified phosphoramidites and lipid conjugates essential for imetelstat sodium.

• Carbosynth
  Provides custom phosphoramidites and oligonucleotide building blocks that are tailored for therapeutic applications.

These chemical suppliers are integral to manufacturing, providing the foundational materials necessary for GMP-grade complex oligonucleotide synthesis.

---

Supply Chain Challenges and Strategic Considerations

The supply of imetelstat sodium faces unique challenges:

• Complex Synthesis Processes:
  The intricate chemical synthesis involving lipid conjugation and phosphoramidite chemistry requires specialized equipment and expertise, limiting the number of qualified manufacturers.

• Regulatory Compliance:
  GMP (Good Manufacturing Practice) standards impose rigorous quality controls, which restrict production to certified facilities. This regulatory environment limits the number of suppliers capable of delivering compliant materials.

• Manufacturing Scalability:
  Transitioning from early-phase clinical supplies to larger production volumes demands significant process validation, which can constrain supply continuity.

• Intellectual Property (IP) and Proprietary Technologies:
  Licensing agreements and proprietary synthesis methods influence supply chain arrangements, with companies often restricting manufacturer options to safeguard IP.

---

Emerging and Future Supplier Trends

The growing interest in oligonucleotide therapeutics has prompted pharmaceutical and biotech companies to invest in expanding their manufacturing capacities. This trend is likely to increase competition among suppliers, improving supply security and reducing costs. Notably:

• Emerging Contract Manufacturers investing in oligonucleotide CDMO services are poised to enter the space, providing alternative sources for imetelstat sodium production.
• Partnerships and Licensing Agreements between Geron and larger pharmaceutical manufacturers could result in diversified manufacturing and supply channels.

---

Implications for Stakeholders

For pharmaceutical companies and investors, understanding and establishing relationships with qualified suppliers is crucial for ensuring uninterrupted supply, especially as imetelstat advances through clinical trials and potential commercialization phases. Strategic sourcing from multiple certified CMOs and chemical suppliers can mitigate supply risks amid regulatory and technological complexities.

---

Conclusion

The supply chain for imetelstat sodium is characterized by a limited number of specialized pharmaceutical and chemical suppliers capable of delivering GMP-grade material. Geron remains the primary developer, leveraging partnerships with advanced oligonucleotide CMOs such as Lonza and Agilent. Emerging manufacturing capacities and continued technological advances are expected to diversify supply sources, ultimately supporting broader clinical development and commercial deployment.

---

Key Takeaways

• Suppliers are predominantly specialized oligonucleotide CMOs with GMP capabilities, notably Lonza and Agilent.
• Chemical reagent vendors such as Sigma-Aldrich and Carbosynth provide critical synthesis materials.
• Manufacturing complexity and strict regulatory standards limit the pool of qualified suppliers.
• Strategic partnerships and investments in oligonucleotide manufacturing are expanding supply options.
• Supply chain resilience hinges on diversifying manufacturing partners and ensuring compliance with GMP regulations.

---

FAQs

1. Who are the primary manufacturers of GMP-grade imetelstat sodium?
Currently, Geron Corporation is the main developer, with GMP production primarily carried out through partnerships with specialized CMOs like Lonza and Agilent, which possess the technical expertise for oligonucleotide synthesis.

2. Can other suppliers produce imetelstat sodium?
While technically feasible, only a few companies possess the requisite GMP-grade manufacturing capacity and technological expertise, limiting production primarily to established oligonucleotide CMOs with regulatory approvals.

3. What challenges do suppliers face in manufacturing imetelstat sodium?
Challenges include complex synthesis methods, rigorous quality control standards, regulatory compliance, and scaling the manufacturing process from early phases to commercial volumes.

4. Are there emerging suppliers or manufacturers entering the imetelstat sodium supply chain?
Yes, increasing investments in oligonucleotide manufacturing capacity and technological advancements are encouraging new entrants, which could diversify supply sources moving forward.

5. How does supply chain complexity impact the commercial prospects of imetelstat sodium?
Supply chain limitations can affect pricing, availability, and the scalability of clinical and commercial supply, influencing portfolio strategy and market potential.

---

Sources

1. Geron Corporation. (2022). Imetelstat Development Program. [Official Website]
2. Lonza Group. (2023). Oligonucleotide Manufacturing Capabilities.
3. Agilent Technologies. (2023). Custom Oligonucleotide Synthesis.
4. MilliporeSigma. (2023). Chemical Reagents for Nucleic Acid Synthesis.
5. ClinicalTrials.gov. (2023). Imetelstat Clinical Trials Data.